Study Stopped
slow enrollment
Shockwave Assisted Large Bore Access
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Annually, 150-200 TAVR with unilateral large bore access and 200 combined TEVAR/EVAR/FEVAR with bilateral large bore access are performed at our institution. Nearly 50 percent of patients fall outside IFU for access vessel size. Adjuncts described include iliac conduit, crack and pave, balloon expandable sheaths, direct aortic puncture, transcaval delivery, alternative access point (i.e axillary, carotid). Each of these adjuncts comes with additional complication potential and by nature of being used less frequently than the standard femoral access makes the procedure more challenging. The intervention the use of the Shockwave Medical, Inc. Peripheral Lithoplasty® System to achieve large bore access in patients whose vessels fall outside of the IFU suggested dimensions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2020
CompletedFirst Posted
Study publicly available on registry
October 23, 2020
CompletedStudy Start
First participant enrolled
October 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 28, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 28, 2023
CompletedSeptember 3, 2024
September 1, 2023
12 months
October 19, 2020
August 29, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Successful advancement of planned large bore access device
Technical success-defined as successful advancement of planned large bore access device without use of additional adjuncts (stenting, repeat shockwave treatment, high pressure balloon, alternative access pathway)
Day 1
Study Arms (2)
Standard POBA (plain old balloon angioplasty)
ACTIVE COMPARATORThe first 50 patients will be pre-treated with standard POBA
Shockwave
EXPERIMENTALThe second 50 patients will be treated primarily with Shockwave
Interventions
Eligibility Criteria
You may qualify if:
- Age \>18 years
- Indicated for planned procedure requiring large bore (\>12 French sheath) access
- Mental capacity to provide informed consent
- Iliac access vessel demonstrates \>50% circumferential calcium
- Iliac access vessel demonstrates maximum inner lumen diameter less than IFU for device required
- Iliac access vessel demonstrates maximum outer wall diameter greater than or equal to IFU for device required
- Preoperative CT angiogram, \</= 5mm slices
- Preoperative ABI/TP
- Unsuccessful delivery of large bore sheath without adjunctive intervention
- o Definition of unsuccessful = operator assessment of the following
- Visible distortion of iliac artery calcification under fluoroscopy without forward progress of device
- Adverse forward pressure application by operator
- Failure of device to track with external pressure applied to abdomen
- Patient intolerance of advancement (pain response) in awake patient
You may not qualify if:
- Contraindicated for antiplatelet therapy (aspirin or plavix)
- Planned iliofemoral surgical reconstruction in next 30 days
- Prior common or external iliac artery stent placement
- Prior aorto-iliac, aorto-femoral, or iliofemoral bypass present
- Iliac access vessel demonstrates maximum outer wall diameter less than IFU for device required
- Inability to obtain preoperative CTA (contrast allergy, CKD, etc)
- Inability to traverse iliac segment with wire
- Emergent procedure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medical University of South Carolinalead
- Shockwave Medical, Inc.collaborator
Study Sites (1)
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mathew Wooster, MD
Medical University of South Carolina
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
October 19, 2020
First Posted
October 23, 2020
Study Start
October 3, 2022
Primary Completion
September 28, 2023
Study Completion
September 28, 2023
Last Updated
September 3, 2024
Record last verified: 2023-09